Gastrocure

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Gastrocure

What is Gastrocure?

Gastrocure is a pharmacological intervention categorized as a proton pump inhibitor (PPI). It is primarily utilized in the management of acid-related disorders of the upper gastrointestinal tract. By targeting the enzymatic pathways within the gastric mucosa, it modulates the production of stomach acid to facilitate the healing of tissue and the relief of symptoms associated with excessive acidity.

Mechanism of Action

The active components in Gastrocure work by inhibiting the H^+/K^+-ATPase enzyme system, commonly referred to as the gastric proton pump. This enzyme is located on the secretory surface of the parietal cells in the stomach lining and represents the final stage of acid secretion. By binding to these pumps, Gastrocure effectively reduces the volume of hydrochloric acid released into the gastric lumen.

Clinical Applications

Gastrocure is indicated for several conditions where a reduction in gastric acid secretion is beneficial for recovery and symptom control:

  • Gastroesophageal Reflux Disease (GERD): It is used to manage the backflow of stomach acid into the esophagus, which can cause heartburn and potential damage to the esophageal lining.
  • Gastric and Duodenal Ulcers: The medication assists in the treatment and prevention of sores that develop on the lining of the stomach or the initial part of the small intestine.
  • Zollinger-Ellison Syndrome: It is employed in managing rare pathological conditions characterized by excessive gastric acid production.
  • Erosive Esophagitis: Gastrocure aids in the healing of inflammation and tissue erosion caused by chronic acid exposure.

Therapeutic Goals

The primary objective of Gastrocure therapy is to maintain a gastric pH level that supports the natural repair of the mucosal barrier. By providing a controlled environment with reduced acidity, the medication helps prevent further irritation of the digestive tract, allowing for the resolution of acid-induced lesions and the stabilization of the digestive environment.

What side effects are possible with Gastrocure?

Possible side effects and safety information

This section summarizes the officially documented adverse reactions and safety information for Gastrocure, as classified by government regulatory agencies (e.g., FDA, EMA).

Adverse effects are categorized by the body system affected and the frequency of their occurrence in clinical trials. It is important to note that a patient's symptomatic response to the medicine does not rule out the presence of a serious underlying medical condition.


Adverse Reaction Classification

Frequency Classification Examples of System-Organ Classes Involved
Common (Affecting 1 to 10 users in 100) Gastrointestinal disorders (e.g., diarrhea, abdominal pain, nausea, flatulence, constipation), Nervous System disorders (e.g., headache, dizziness)
Uncommon (Affecting 1 to 10 users in 1,000) Skin and subcutaneous tissue disorders (e.g., rash, pruritus), Metabolism and Nutrition disorders
Rare (Affecting 1 to 10 users in 10,000) Hematologic disorders, Psychiatric disorders (e.g., confusion in the elderly or those with impaired function)

Serious and Clinically Significant Risks

Official labeling documents identify serious adverse reactions that may require medical intervention. These include, but are not limited to:

  • Acute Interstitial Nephritis (AIN): An inflammatory condition affecting the kidneys that can occur at any point during therapy.
  • Bone Fracture Risk: Prolonged and high-dose therapy may be associated with an increased risk for osteoporosis-related fractures of the hip, wrist, or spine.
  • Hypomagnesemia: Low magnesium levels in the blood have been reported with prolonged treatment, sometimes requiring supplementation or discontinuation.
  • Infections: Therapy may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD) and gastrointestinal infections.
  • Systemic Lupus Erythematosus (SLE): New onset or exacerbation of cutaneous or systemic lupus erythematosus has been reported.

Safety Restrictions

Gastrocure is contraindicated in individuals with a known hypersensitivity to the drug or its components. Caution is advised for use in patients with pre-existing conditions such as liver impairment, osteoporosis, or those at risk for Vitamin B-12 deficiency due to long-term use (e.g., over three years). Regulatory guidance specifies that certain warnings, such as the potential for atrophic gastritis, are associated with long-term therapy.

Overdose and Emergency Response

If an accidental or intentional overdose of Gastrocure is suspected, immediate medical attention is required, as this is considered a medical emergency in official regulatory guidance. The information available on overdose is intended for use by healthcare professionals to manage acute toxicity.

Documented Overdose Profile

Official regulatory documents require that the overdose section detail the anticipated signs and symptoms of drug overdose and the potential effects of different dose levels (sequelae). This information is based on human data from both accidental intake and intentional misuse of the substance, including mistakes and suicide attempts.

Symptoms and presentations that necessitate professional medical care may vary but are generally described as acute physical manifestations of toxicity.

Required Emergency Actions

In cases of suspected overdose, prompt medical intervention is essential. Healthcare providers must follow established emergency procedures, which include:

  • Providing recommended general treatment procedures for poisoning.
  • Initiating specific measures for support of vital functions as needed.
  • The use of methods to reduce absorption or increase elimination of the substance may be necessary, such as the use of activated charcoal or other elimination techniques, depending on the specific drug and presentation.

Timely professional assessment in a clinical setting is the only way to determine the extent of exposure and the appropriate course of management.

Therapeutic Uses of Gastrocure

What Gastrocure Treats: Main Uses and Benefits

Gastrocure is commonly used to help with a variety of gastrointestinal issues and may be applied when symptoms intensify and supportive relief is needed. This medication is commonly applied in clinical settings that involve acute or unstable symptom patterns, and is relevant for easing symptoms that interfere with daily comfort.

This class of drugs is used to help relieve symptoms associated with acid reflux and to help manage conditions like stomach or duodenal ulcers. It is considered relevant in conditions characterized by periods of heightened symptoms.

The medication's role is generally supportive. It assists with maintaining functional stability and may support general well-being during symptomatic phases where discomfort may become momentarily overwhelming.


Quick Fact: Assistance for Episodic Discomfort

Quick Fact: Assistance for Episodic Discomfort


Regulatory References

  1. NIH MedlinePlus Overview of Proton Pump Inhibitors

Eligibility and Restrictions for Use

Who can and cannot use Gastrocure?

This section outlines the officially documented population eligibility and restrictions for Gastrocure (Rabeprazole and Domperidone combination), based strictly on government regulatory documents.


Absolute Contraindications (Must Not Use)

Use of Gastrocure is contraindicated in patients with the following conditions, as stated in regulatory labeling:

  • Hypersensitivity to either active ingredient or excipients.
  • Moderate or severe hepatic impairment (liver disease).
  • Existing cardiac risks, including known QTc prolongation, congestive heart failure, or significant electrolyte disturbances.
  • Conditions where stimulating gut movement is harmful, such as gastrointestinal hemorrhage, mechanical obstruction, or perforation.
  • Co-administration with specific medications, including QT-prolonging drugs or potent CYP3A4 inhibitors.

Eligibility Based on Age and Physiological Status

Population Group Regulatory Status
Children and Adolescents (Under 18) Not recommended due to a lack of sufficient data on safety and efficacy for the combination.
Pregnancy Contraindicated.
Lactation (Breastfeeding) Contraindicated and must not be used.
Severe Renal Impairment Requires caution; a reduced dosing frequency is necessary, as stated in the label.

Gastrocure is primarily indicated and permitted for use in adults aged 18 years and older, though caution is required for older adults.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Gastrocure contains Rabeprazole (a Proton Pump Inhibitor) and Domperidone (a Prokinetic agent), resulting in two distinct interaction profiles documented in regulatory labeling.

Contraindicated Combinations

Co-administration with the Domperidone component is formally contraindicated with both Potent CYP3A4 Inhibitors (e.g., Clarithromycin, systemic Azole Antifungals) and all known QT c -Prolonging Medicines due to the increased risk of serious ventricular arrhythmias. Co-administration with the Rabeprazole component and Rilpivirine is also contraindicated, as the resulting acid suppression significantly reduces Rilpivirine plasma concentration.

Exposure-Modifying and Timing Interactions

The acid-reducing effect of Rabeprazole can decrease the absorption and exposure ( AUC/ C max) of pH-dependent absorption drugs, including certain HIV Protease Inhibitors (e.g., Atazanavir) and Azole Antifungals. Conversely, concomitant use with high-dose Methotrexate may lead to elevated serum levels of Methotrexate. For the Domperidone component, co-administration with Antacids or antisecretory agents must be separated in time, as simultaneous use lowers its oral bioavailability. Furthermore, Domperidone is contraindicated in patients with moderate or severe hepatic impairment due to increased accumulation and interaction risk.

Mechanism of Action

Targeted Blockade of the Histamine-2 ( H2) Receptor

Gastrocure initiates its action by operating within the mechanistic domain of receptor-mediated signaling, acting as a selective antagonist for the H2 receptors found on the stomach's parietal cells. This interaction directly suppresses the signaling sequence that normally leads to acid production, thereby modifying the early molecular steps that shape gastric physiological outcomes.

Modulation of the Gastric Secretory Pathway

The drug's activity engages mechanisms that influence overactive secretory processes. By blocking H2 signaling, Gastrocure alters pathway activity in the cyclic AMP (cAMP) cascade, which is necessary for activating the final acid-secreting pumps. This results in modulation of the pathway activity, which results in the physiological adjustment of reduced acid output.

Influence on Basal and Stimulated Secretion

Gastrocure is relevant in systems where targeted pathway adjustment is required to influence mediator-driven responses. Its mechanism modifies the intensity of signals that influence both the resting (basal) and the meal-triggered (stimulated) rates of acid secretion. This action influences the intensity of overactive physiological responses by reducing the downstream effects of excessive histamine-driven activity.

Dosage and Administration Information

How Gastrocure is Used: Official Administration Guidelines

The use of Gastrocure is governed by established guidelines regarding its administration, frequency, and timing. The medicine is delivered by the oral route as a fixed-dose combination, with each unit containing Rabeprazole 20mg and Domperidone 10mg.

Instruction Detail
Dosing Schedule One unit (capsule or tablet) once daily.
Timing Administered approximately 30 minutes prior to the morning meal.
Preparation Must be swallowed whole with water; should not be chewed, crushed, or split.
Course Duration Limited to short-term courses, typically lasting four to eight weeks.

The dosing schedule is standardized to one unit once daily, with the timing specifically linked to the morning meal to ensure the optimal function of the combination's components. Furthermore, the instructions involve procedural restrictions on intake; the unit must be swallowed whole to preserve the integrity of the enteric-coated Rabeprazole component.

Specific adjustments are noted for certain patient populations: individuals with severe hepatic impairment may require dose reduction or restricted use. If a daily dose is missed, it should be skipped if the next scheduled time is close; the dose must never be doubled to compensate.

Recent Clinical Evidence

Gastrocure: Recent Clinical Evidence


Evidence for Use in Gastroesophageal Reflux Disease (GERD) and Nighttime Heartburn

Research exploring Gastrocure was primarily conducted in adult patients with GERD and persistent symptoms. Studies were typically short-term Randomized Controlled Trials (RCTs) examining outcomes related to heartburn severity and healing rates of erosions. Some comparative studies described patterns where the combination group and the acid-reducing ingredient alone group reported different measurements in global symptom scores. Follow-up durations were limited, mainly to 4 to 8 weeks, and the generalizability of the findings may be limited by the focus on specific regional populations.


Evidence for Use in Functional Dyspepsia (FD) and Motility Disorders

Research into the prokinetic ingredient was conducted in study participants with Functional Dyspepsia (FD) and related motility issues. Studies monitored outcomes related to functional scales and gastric emptying time. The overall evidence base for the specific combination is often assigned a Moderate classification, as the data are drawn from a mix of RCTs and observational settings. Subgroup findings are uncertain due to heterogeneity in defining FD populations across different studies.


Evidence for Use in Laryngopharyngeal Reflux Disease (LPRD)

Research exploring the combination in conditions causing upper airway symptoms (LPRD) involved open-label, single-centre trials. Researchers monitored specialized functional scales (RSI and RFS) over intermediate follow-up periods, typically 12 weeks. The evidence level for this fixed combination is generally classified as Low due to modest sample sizes and non-comparative designs in some studies.


Research Gaps and Uncertainty

The majority of studies monitored adult patients, and data was observed to be insufficient in children, older adults, or pregnant populations. Limited information for long-term outcomes is a recognized gap, as most trials primarily explored changes in measured variables over short time intervals. One key limitation is that sample sizes were modest in some specific indications, and comparative evidence against all alternative treatments is still lacking in certain areas.

Key Studies & References

  1. Dom R Capsules Enteric coated Rabeprazole Sodium and Domperidone SR Capsules 3 x 10 Alu/Alu - Summary of Product Characteristics (SmPC)
  2. Real-World Safety and Effectiveness of Rabeprazole–Domperidone Fixed-Dose Combination (Happi D) in Gastroesophageal Reflux Disease
  3. The Impact of Proton Pump Inhibitors on Laryngopharyngeal Reflux Disease

Frequently Asked Questions (FAQ)

Common questions about Gastrocure (FAQ)


Q: How quickly does Gastrocure start working?

A: Studies on the acid-suppressing component indicate that its anti-secretory effect begins relatively quickly, often within about one hour after the capsule or tablet is taken. However, the full therapeutic benefit, such as healing conditions, is generally evaluated over the prescribed course of treatment, not just by the initial onset.

Q: What is the longest I can safely take Gastrocure for?

A: Official indications for the acid-reducing ingredient generally recommend limiting short-term treatment to a duration of four to eight weeks for specific conditions. Maintenance of healing has been studied for up to twelve months. Regulatory warnings highlight the risks, such as bone fracture and nutrient deficiency, associated with long-term and high-dose therapy of the acid-reducing component.

Q: Can I take Gastrocure every day?

A: The approved standard dosing schedule for this fixed combination is to take it once daily. The overall duration of daily use is typically limited to a short-term course, such as the 4 to 8 weeks often cited for specific conditions, according to product information.

Q: Does Gastrocure affect my sleep?

A: Official safety profiles for the individual ingredients, as documented in regulatory sources, list potential central nervous system (CNS) effects such as dizziness and somnolence (sleepiness). If changes to sleep are experienced, official guidance outlines that these or other potential CNS effects should be discussed with a qualified professional.

Q: Can Gastrocure cause long-term kidney issues?

A: Regulatory warnings indicate that the acid-reducing component has been associated with Acute Interstitial Nephritis (AIN), which is an inflammatory condition of the kidney. This condition can occur at any time during therapy, and regulatory safety guidance emphasizes the importance of clinical monitoring for all serious adverse reactions.

Q: What should I do if I miss a dose of Gastrocure?

A: Regulatory instructions provide specific steps for managing a missed dose, generally advising against doubling the dose to compensate. Details on what to do when a dose is missed are found in the official administration guidelines, which should be followed carefully.

Q: Is there a generic version of Gastrocure available?

A: Gastrocure is a brand name medicine. Its active ingredients, Rabeprazole (a Proton Pump Inhibitor) and Domperidone (a Prokinetic), are available as individual generic medicines, depending on the region.

Q: Does Gastrocure interact with blood pressure medications?

A: Yes, the Domperidone component is contraindicated (must not be used) with many medications that can affect heart rhythm, including some QT c-prolonging drugs. For any medication in these classes, regulatory guidance emphasizes the importance of reviewing the entire medication list with a professional.

Q: Are there any herbal supplements that interact with Gastrocure?

A: The Rabeprazole component may interfere with the absorption of certain other compounds. While a comprehensive list is not provided, some drug interaction sources advise caution when Gastrocure is taken alongside St John's Wort, a commonly used herbal supplement.

Q: Is it safe to take Gastrocure with ibuprofen (Advil)?

A: Before combining Gastrocure with any over-the-counter pain relievers, including Ibuprofen, official safety principles require a review of potential interactions with a qualified professional. Regulatory documents advise caution when using the drug alongside other medicines.

Q: Is Gastrocure safe for people over 65?

A: Caution is advised for older adults. Regulatory warnings indicate that a higher cardiac risk has been observed with the Domperidone component in patients older than 60 years. This patient group may require specific patient monitoring according to regulatory guidance.

Q: What evidence supports the use of Gastrocure for ulcers?

A: Regulatory sources state that the Rabeprazole component is approved for the healing of duodenal ulcers. Furthermore, it is often used as part of a regimen to help eradicate the H. pylori bacteria, a major cause of recurrent peptic ulcers.

Q: Does Gastrocure cure the underlying condition or just manage symptoms?

A: Gastrocure's mechanism is to suppress acid production and increase gut movement, which primarily provides symptom management. Official warnings emphasize that a patient's positive response to the medicine does not preclude the presence of a serious underlying medical condition.

Q: Is Gastrocure absorbed into the bloodstream?

A: Yes, both active ingredients, Rabeprazole and Domperidone, are absorbed following oral administration. The Rabeprazole component reaches peak plasma concentrations in the blood and is then primarily eliminated through the urine.

Q: What happens if I suddenly stop taking Gastrocure?

A: Stopping any medication should be done under professional guidance. The Domperidone component is associated with risks upon sudden cessation, and abrupt discontinuation of the PPI component can sometimes lead to temporary rebound acid hypersecretion.

Q: Can Gastrocure cause vitamin deficiencies?

A: Yes, regulatory warnings note that prolonged treatment with the acid-reducing component may be associated with an increased risk of Vitamin B 12 deficiency. There is also a risk of Hypomagnesemia (abnormally low magnesium levels in the blood).

Q: Is Gastrocure known to interact with alcohol?

A: Official safety warnings advise that drinking alcohol may potentially decrease the medicine's overall effectiveness. Alcohol is known to cause dehydration and can elevate stomach acid levels, which counteracts the drug's intended action.

Q: Can Gastrocure be taken with vitamins?

A: The acid-reducing component (Rabeprazole) has the potential to interfere with the absorption of compounds whose uptake depends on stomach acid levels, such as iron salts. Official safety information is required when combining any other compounds with this medication.

Q: Is there a maximum daily dosage for Gastrocure?

A: The standard maximum dose for typical conditions like GERD is one unit (containing 20 mg Rabeprazole and 10 mg Domperidone) once daily. Regulatory information confirms this is the authorized dosage for the fixed combination.

Q: Do I need to take Gastrocure with food?

A: Official instructions specify that the medicine should be administered approximately 30 minutes prior to the morning meal. Taking the medicine after a meal may delay the absorption and overall effectiveness of the Domperidone component.

Q: Why is it important to tell my doctor about other medicines before starting Gastrocure?

A: This is necessary because Gastrocure is strictly contraindicated (must not be used) with several classes of medicines, including certain heart rhythm drugs and potent CYP3A4 inhibitors. Regulatory guidance requires this step for patient safety, as the drug can alter the absorption of other essential medicines.

Q: How long until the full benefit of Gastrocure is reached?

A: Clinical trials for healing conditions like erosive gastroesophageal reflux disease (GERD) typically monitor patients over a full four to eight week course. This duration suggests that the maximum, sustained therapeutic benefit is evaluated and achieved after several weeks of continuous administration.

Q: Will Gastrocure interact with common cold medicine?

A: Regulatory documents warn against using Gastrocure with medicines that can prolong the QT c interval on the heart. Some common cold or cough medicines, such as those containing certain antihistamines or decongestants, may fall into this category, requiring caution and professional review.

Q: Are there any warning signs for severe side effects from Gastrocure?

A: Official safety warnings list several serious risks. Potential warning signs for these conditions include unusual pain or signs of bleeding (for bone fracture risk), unusual changes in urination or blood in urine (for Acute Interstitial Nephritis), and symptoms like muscle spasms or an irregular heartbeat (for Hypomagnesemia).

Q: Can Gastrocure affect the results of lab tests?

A: Yes, the Rabeprazole component can potentially affect the results of certain laboratory tests. This includes the International Normalized Ratio (INR) for patients taking the blood thinner Warfarin, and the medicine can lead to low magnesium levels (Hypomagnesemia), which is confirmed via blood tests.

Q: Is it better to take Gastrocure in the morning or at night?

A: The official administration instructions require the medicine to be taken in the morning, specifically approximately 30 minutes prior to the morning meal. This timing is necessary to optimize the dual action and absorption of the drug's components.

How should Gastrocure be stored and disposed of?

How to Store and Dispose of Gastrocure

Official regulatory information requires that Gastrocure, containing rabeprazole and domperidone, be stored under specific conditions to maintain product stability and protect the enteric coating.


Storage Requirements

Condition Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Keep the container tightly closed and store in a dry place to protect from moisture.
Handling Tablets or capsules must not be chewed, crushed, or split.
Child Safety Store the medication locked up and out of the reach of children.

Disposal Instructions

Unused or expired medication should be disposed of via a drug take-back program when available. If not, the FDA-recommended household disposal method involves mixing the medicine with an unappealing substance, placing the mixture in a sealed container, and discarding it in the trash. The medication should not be allowed to enter sewers or waterways.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Gastrocure found in:

A-Z Index: